ISOCLIMA SPECIALTY GLASS, LLC – Trademark Portfolio
Entity Type: 16
ISOCLIMA SPECIALTY GLASS, LLC owns a portfolio of 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as LEXGARD, TORGARD, CHEM-TEM, ARMORGARD, and ACCESSGARD. Of these, 9 are registered and 5 are pending. The portfolio spans 4 Nice Classification classes, led by Class 19 (Building Materials) and Class 9 (Computers & Electronics). Headquartered in SELMA, AL.
616 SELFIELD ROAD
SELMA, AL 36703
Showing of trademarks Trademarks
Trademark Classifications
ISOCLIMA SPECIALTY GLASS, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Building materials (non-metallic); non-metallic rigid pipes for building
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does ISOCLIMA SPECIALTY GLASS, LLC have?
ISOCLIMA SPECIALTY GLASS, LLC has 14 U.S. trademarks filed with the USPTO. Of these, 9 registered, 5 pending.
What trademark classes does ISOCLIMA SPECIALTY GLASS, LLC file in?
ISOCLIMA SPECIALTY GLASS, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 19 (Building Materials), Class 9 (Computers & Electronics), Class 17 (Rubber Goods), Class 12 (Vehicles). Class 19 covers building materials (non-metallic); non-metallic rigid pipes for building.
What are ISOCLIMA SPECIALTY GLASS, LLC's most well-known trademarks?
ISOCLIMA SPECIALTY GLASS, LLC's registered trademark portfolio includes well-known marks such as LEXGARD, TORGARD, CHEM-TEM, ARMORGARD, and ACCESSGARD. These are among 9 currently registered trademarks in the portfolio.
What is ISOCLIMA SPECIALTY GLASS, LLC's trademark registration success rate?
ISOCLIMA SPECIALTY GLASS, LLC has a 100% trademark registration rate, with 9 out of 9 resolved applications resulting in successful registration. Currently, 5 applications are pending review.